Loading clinical trials...
Loading clinical trials...
A Phase I Trial of CBT-1® in Combination With Doxorubicin in Patients With Locally Advanced or Metastatic, Unresectable Sarcomas Previously to Have Progressed on 150 mg/m2 or Less of Doxorubicin
Conditions
Interventions
CBT-1®
Locations
6
United States
Sarcoma Oncology Research Center
Santa Monica, California, United States
Mayo Clinic
Jacksonville, Florida, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Seattle Cancer Care Alliance
Seattle, Washington, United States
Start Date
March 29, 2018
Primary Completion Date
September 1, 2020
Completion Date
September 1, 2020
Last Updated
August 19, 2019
NCT04704661
NCT06066138
NCT05039801
NCT03715933
NCT07479732
NCT07156565
Lead Sponsor
CBA Research
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions